- Home
- ZDGE vs OTLK Comparison
ZDGE vs OTLK Comparison
Compare ZDGE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- OTLK
- Stock Information
- Founded
- ZDGE 2008
- OTLK 2010
- Country
- ZDGE United States
- OTLK United States
- Employees
- ZDGE N/A
- OTLK N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZDGE Technology
- OTLK Health Care
- Exchange
- ZDGE Nasdaq
- OTLK Nasdaq
- Market Cap
- ZDGE 40.3M
- OTLK 48.3M
- IPO Year
- ZDGE N/A
- OTLK 2016
- Fundamental
- Price
- ZDGE $3.99
- OTLK $1.75
- Analyst Decision
- ZDGE
- OTLK Strong Buy
- Analyst Count
- ZDGE 0
- OTLK 5
- Target Price
- ZDGE N/A
- OTLK $9.60
- AVG Volume (30 Days)
- ZDGE 418.5K
- OTLK 786.0K
- Earning Date
- ZDGE 06-12-2025
- OTLK 08-13-2025
- Dividend Yield
- ZDGE N/A
- OTLK N/A
- EPS Growth
- ZDGE N/A
- OTLK N/A
- EPS
- ZDGE N/A
- OTLK 0.83
- Revenue
- ZDGE $29,511,000.00
- OTLK N/A
- Revenue This Year
- ZDGE N/A
- OTLK N/A
- Revenue Next Year
- ZDGE $1.07
- OTLK $379.84
- P/E Ratio
- ZDGE N/A
- OTLK $2.11
- Revenue Growth
- ZDGE 1.27
- OTLK N/A
- 52 Week Low
- ZDGE $1.73
- OTLK $0.87
- 52 Week High
- ZDGE $4.38
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- ZDGE 84.28
- OTLK 50.96
- Support Level
- ZDGE $2.55
- OTLK $1.65
- Resistance Level
- ZDGE $4.37
- OTLK $2.04
- Average True Range (ATR)
- ZDGE 0.36
- OTLK 0.12
- MACD
- ZDGE 0.11
- OTLK -0.02
- Stochastic Oscillator
- ZDGE 79.29
- OTLK 25.64
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.